信立泰股价小幅下跌 半年度净利润同比增长6.10%

Core Viewpoint - The company Xintai's stock price has experienced a slight decline, while its financial performance shows moderate growth in revenue and net profit, supported by significant R&D investment and new product approvals [1] Financial Performance - As of August 20, 2025, Xintai's stock price is 50.24 yuan, down 0.57% from the previous trading day [1] - The company reported a revenue of 2.131 billion yuan for the first half of 2025, representing a year-on-year increase of 4.32% [1] - The net profit attributable to shareholders for the same period was 365 million yuan, reflecting a year-on-year growth of 6.10% [1] - R&D expenditure reached 542 million yuan, accounting for 25.43% of total revenue [1] Product Development - New products, Xinchao Tuo and Fuli An, have been approved for market launch, contributing to a differentiated product portfolio in the hypertension treatment sector [1] Market Activity - On August 20, 2025, the net outflow of main funds was 52.36 million yuan, while there was a net inflow of 33.40 million yuan over the past five days [1] - As of August 19, 2025, a total of 86 institutional investors held shares in the company, with a combined holding ratio of 74.71% [1]